Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;51(7):1955-1964.
doi: 10.1007/s00259-024-06643-8. Epub 2024 Feb 14.

Prognostic value of baseline and interim [18F]FDG PET metabolic parameters in pediatric Hodgkin's lymphoma

Affiliations

Prognostic value of baseline and interim [18F]FDG PET metabolic parameters in pediatric Hodgkin's lymphoma

Mikhail Ya Yadgarov et al. Eur J Nucl Med Mol Imaging. 2024 Jun.

Abstract

Background: Hodgkin lymphoma (HL) in pediatric populations has a high survival rate but poses risks for long-term morbidities. Although [18F]fluoro‑2‑deoxy‑2‑d‑glucose positron emission tomography ([18F]FDG PET) scans offer potential for improved risk stratification, the definitive prognostic value of quantitative [18F]FDG PET parameters remains unclear for pediatric HL.

Methods: A single-center, retrospective study included pediatric patients diagnosed with HL between 2016 and 2023 treated according to EuroNet-PHL-C1 and DAL/GPOH-HD protocols. Patients underwent baseline and interim PET/CT scans after two chemotherapy cycles. Event-free survival (EFS) was the primary endpoint, Deauville score was the secondary endpoint. Quantitative [18F]FDG PET parameters included SUVmax, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) that were evaluated using two segmentation methods (SUV 2.5, 41% SUVmax). Survival outcomes were assessed using Cox regression analysis.

Results: A total of 115 patients (50 males, median age 14.2 years) were studied, with a median follow-up period of 35 months. During this period, 16 cases (13.9%) of relapse or progression were noted. Baseline and interim MTV 2.5, MTV 41%, TLG 2.5, and TLG 41%, along with interim SUVmax, were significantly associated with worse EFS and correlated with post-treatment Deauville scores. In multivariable analysis, interim MTV 2.5 > 0 ml (adj. hazard ratio, HR: 3.89, p = 0.009) and interim TLG 41% ≥ 30 g (adj. HR: 7.98, p = 0.006) were independent risk factors for EFS.

Conclusion: Baseline and interim [18F]FDG PET parameters can serve as significant prognostic indicators for EFS and treatment response in pediatric HL. These quantitative measures could enhance individualized, risk-adapted treatment strategies for children and adolescents with HL.

Keywords: Event-free survival; Metabolic tumor volume; Pediatric Hodgkin Lymphoma; Segmentation; Total lesion glycolysis; [18F]FDG PET.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Kahn JM, Pei Q, Friedman DL, et al. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children’s oncology group trials. Lancet Haematol. 2022;9:e49-57. https://doi.org/10.1016/S2352-3026(21)00349-5 . - DOI - PubMed - PMC
    1. Perez-Callejo D, Zurutuza L, Royuela A, et al. Long-term follow up of Hodgkin lymphoma. Oncotarget. 2018;9:11638–45. https://doi.org/10.18632/oncotarget.24392 . - DOI - PubMed - PMC
    1. Kelly KM, Cole PD, Pei Q, et al. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. Br J Haematol. 2019;187:39–48. https://doi.org/10.1111/bjh.16014 . - DOI - PubMed - PMC
    1. Van Nimwegen FA, Schaapveld M, Janus CPM, et al. Cardiovascular disease after hodgkin lymphoma treatment 40-year disease risk. JAMA Intern Med. 2015;175:1007–17. https://doi.org/10.1001/jamainternmed.2015.1180 . - DOI - PubMed
    1. Holmqvist AS, Chen Y, Berano Teh J, et al. Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma—Identification of high-risk populations to guide surveillance: A report from the Late Effects Study Group. Cancer. 2019;125:1373–83. https://doi.org/10.1002/cncr.31807 . - DOI - PubMed

Substances

LinkOut - more resources